Affiliation:
1. University of Colorado Cancer Center, PO Box 6511, Mailstop 8111, Aurora, CO 80045, USA.
Abstract
Pemetrexed is a new generation antifolate anticancer agent that inhibits several folate-dependent enzymes required for production of DNA and RNA intermediates. Early studies showed significant hematologic and nonhematologic toxicities with this agent. However it was found that many of these toxicities related to functional folate status and could be markedly reduced through routine supplementation with folic acid and vitamin B12, without adversely affecting efficacy. Phase III studies with pemetrexed have established a clinical role for this drug as a single agent in the second-line treatment of non-small cell lung cancer and in combination with cisplatin for the frontline treatment of unresectable malignant pleural mesothelioma. Clinical trials of pemetrexed alone or in combination with other chemotherapeutic agents have shown considerable activity in many tumor types including colorectal, pancreatic and breast cancer, and urothelial tumors.
Subject
Cancer Research,Oncology,General Medicine
Reference77 articles.
1. ShihC, Chen VJ, Gossett LSet al.: LY-231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.Cancer Res.57(6),1116–23 (1997).
2. ShihC, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY-231514 (MTA).Adv. Enzyme Regul.38,135–52 (1998).
3. Molecular, biochemical, and cellular pharmacology of pemetrexed
4. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献